Crossmark

The ups and downs of paclitaxel-coated balloons and paclitaxel eluting stents: do the conclusions of SWEDEPAD 2 change our practice? Should we be concerned about mortality (again)?

Crossref DOI link: https://doi.org/10.1186/s42155-025-00645-9

Published Online: 2026-01-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Müller-Hülsbeck, Stefan https://orcid.org/0000-0001-6011-9466
Fanelli, Fabrizio

Haage, Patrick

Hamady, Mohamad

Kobeiter, Hicham

Loffroy, Romaric

O’Sullivan, Gerard

Ratnam, Lakshmi A.

van Rijswijk, Catharina S. P.

Ruffino, Maria Antonella

Wolf, Florian

Morgan, Robert A.
License Information

Text and Data Mining valid from 2026-01-27

Version of Record valid from 2026-01-27
More Information

Article History

Received: 13 November 2025

Accepted: 22 December 2025

First Online: 27 January 2026

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below